Get started
Assertio Holdings, Inc.Assertio Holdings, Inc.Assertio Holdings, Inc.

Assertio Holdings, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

ASRT trade ideas

ASRT can do this?"Assertio is a pharmaceutical company that sells prescription products in 3 areas: neurology, hospital, and pain and inflammation. The company is currently undergoing major restructuring and has recently merged with Zyla Life Sciences. They have 7 FDA approved products in the marketplace. Assertio currently has a market cap of only $150 million and has raised $50 million in direct offerings over the past week. ASRT has been on a bullish run with the price is currently up 45% in 1 week and it closed at $1.09 yesterday. This is despite 2 offerings that have been announced. The price skyrocketed off the closure of the first offering priced at $0.62 and I believe it will do the same with the current offering. Prior to the announcement of the recent offering (@$0.98), the price hit $1.45 on Tuesday. Given that the offering will not result in dilution, I believe any price under $1.1 is a good buy point" Quoting - u/TruePriest My target is 3$ depending on the earnings report next month. My RR ratio is 1:4 While we speak let's just avg down or up. (Disclaimer) (This is not financial advice, just my opinion)
NASDAQ:ASRTLong
by jackohgorman
1
$ASRT can rise in the next daysContextual immersion trading strategy idea. Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,02; stop-loss — $0,95. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ASRTLong
by KozakHlib
Assertio Therapeutics, Inc. rallies on Deal Collegium Pharmaceutical (NASDAQ:COLL) +8.3% after-hours on news it agrees to acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics (NASDAQ:ASRT) for $375M; ASRT +56.7%. Collegium calls the deal "financially transformative... We expect the acquisition to improve annual EBITDA and operating cash flows by more than $100M." The company says the Nucynta franchise, which includes an extended-release and an immediate release formulation of tapentadol, is supported by patents with expires in mid-June 2025, with the potential for a six-month pediatric extension. Source seeking alpha Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
NASDAQ:ASRTLong
by DEXWireNews
1
High-risk, high-reward drug catalyst play on ASRTAssertio therapeutics is slated to get an FDA ruling on its new drug application for cosyntropin depot by October 19. If the FDA approves the drug, the stock could move up significantly. Assertio has an 8.9/10 Equity StarMine Summary Score and is rated extremely undervalued by S&P Capital IQ. Despite relatively good earnings last quarter, the stock price is down due to a stock offering after the earnings report. Assertio also has a lot of exposure to litigation or regulation around opioids, because its most successful drug is an opiate. A new drug approval could shake the stock out of its lethargy and give it a really nice boost. Short interest in the stock is reasonably high, at 15% of float, which could contribute to a short squeeze. Of course, failure to get approval would send the stock tumbling.
NASDAQ:ASRTLong
by ChristopherCarrollSmith
2